基于CiteSpace分析2011年—2020年全球肝癌免疫治疗研究领域的热点及趋势

张稚淳; 孙力超; 孙秋月; 彭亮; 田古

doi:10.3969/j.issn.1001-5256.2021.12.022

基于CiteSpace分析2011年—2020年全球肝癌免疫治疗研究领域的热点及趋势

DOI: 10.3969/j.issn.1001-5256.2021.12.022

张稚淳¹,
孙力超^{1, 2a},
孙秋月¹,
彭亮³,
田古^2b, ,

1.
北京中医药大学东直门医院重点实验室，北京 100700
2a.
国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院分子肿瘤重点实验室，北京 100021
2b.
国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院科研处，北京 100021
3.
中日友好医院北京市免疫炎性重点实验室，中日友好医院临床医学研究所，北京 100029

基金项目:

国家自然科学基金面上项目 (81773170)

详细信息

通信作者:
田古, tiangu@cicams.ac.cn

中图分类号: R735.7
计量
- 文章访问数: 465
- HTML全文浏览量: 98
- PDF下载量: 46
- 被引次数: 0
出版历程
- 收稿日期: 2021-05-10
- 录用日期: 2021-06-15
- 出版日期: 2021-12-20

Global research hotspots and trends in the field of immunotherapy for liver cancer in 2011-2020 based on CiteSpace analysis

Zhichun ZHANG¹,
Lichao SUN^{1, 2a},
Qiuyue SUN¹,
Liang PENG³,
Gu TIAN^{2b
, ,}

1.
Key Laboratory, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China
2a.
State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2b.
Office of Academic Research, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
3.
Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China

Research funding:

National Natural Science Foundation of China (81773170)

摘要

摘要: 目的通过文献计量学方法分析2011年—2020年全球肝癌免疫治疗领域的研究热点和研究趋势。方法选取Web of Science-SCI Expanded数据库，检索策略：#1 TS=(Liver Neoplasms OR Neoplasms，Hepatic OR Neoplasms，Liver OR Liver Neoplasm OR Neoplasm，Liver OR Hepatic Neoplasms OR Hepatic Neoplasm OR Neoplasm，Hepatic OR Cancer of Liver OR Hepatocellular Cancer OR Cancers，Hepatocellular OR Hepatocellular Cancers OR Hepatic Cancer OR Cancer，Hepatic OR Cancers，Hepatic OR Hepatic Cancers OR Liver Cancer OR Cancer，Liver OR Cancers，Liver OR Liver Cancers OR Cancer of the Liver OR Cancer，Hepatocellular)AND #2 TS=(Immunotherapy OR Immunotherapies OR Immunity therapy)，时间跨度：2011年—2020年，文献类型：Article，语种：English。通过CiteSpace软件对2011年—2020年肝癌免疫治疗领域发表文献的年度、国家、机构、作者、期刊、基金分布、被引情况以及关键词等进行可视化分析，分析该领域文献关键词词频、中心性和聚类情况。结果共纳入1972篇肝癌免疫治疗文献，分析结果显示，中国是发文量最多的国家，中山大学是发文量最多的机构，Journal for Immunotherapy of Cancer是发文量最多的期刊。肿瘤相关巨噬细胞、溶瘤病毒(如腺病毒)、肿瘤疫苗、过继免疫细胞、免疫检查点抑制剂及免疫联合治疗是当前该领域研究热点。肿瘤疫苗→溶瘤病毒免疫治疗→过继免疫细胞治疗→免疫检查点抑制剂治疗是该领域的研究趋势。结论近10年来，肝癌免疫治疗研究不断发展，随着新的肿瘤疫苗、溶瘤病毒和免疫检查点抑制剂的研发，免疫检查点抑制剂的改进，以免疫治疗为基础的联合治疗有望进一步提高肝癌的临床疗效。
- 癌，肝细胞 /
- 免疫疗法 /
- 文献计量学 /
- CiteSpace
Abstract: Objective To investigate the research hotspots and trends in the field of immunotherapy for liver cancer in 2011-2020 based on bibliometric methods. Methods The Web of Science-SCI Expanded database was searched with the following search strategy: #1 TS = (Liver Neoplasms OR Neoplasms, Hepatic OR Neoplasms, Liver OR Liver Neoplasm OR Neoplasm, Liver OR Hepatic Neoplasms OR Hepatic Neoplasm OR Neoplasm, Hepatic OR Cancer of Liver OR Hepatocellular Cancer OR Cancers, Hepatocellular OR Hepatocellular Cancers OR Hepatic Cancer OR Cancer, Hepatic OR Cancers, Hepatic OR Hepatic Cancers OR Liver Cancer OR Cancer, Liver OR Cancers, Liver OR Liver Cancers OR Cancer of the Liver OR Cancer, Hepatocellular) AND #2 TS = (Immunotherapy OR Immunotherapies OR Immunity therapy); time span: 2011-2020; type of literature: Article; language: English. CiteSpace software was used to perform a visualized analysis of the articles in the field of immunotherapy for liver cancer published in 2011-2020 from the aspects of the distributions of year, country, institution, author, journal, and fund, times cited, and keywords, and the frequency, centrality, and clustering of keywords were discussed. Results A total of 1972 articles on immunotherapy for liver cancer were included, and the analysis showed that China was the country with the largest number of articles, Sun Yat-sen University was the institution with the largest number of articles, and Journal for Immunotherapy of Cancer was the journal with the largest number of articles. The research hotspots in this field included tumor-associated macrophages, oncolytic virus (such as adenovirus), tumor vaccine therapy, adoptive cellular immunotherapy, immune checkpoint inhibitors, and combined immunotherapy. The trend of this field was tumor vaccine therapy → immunotherapy for oncolytic virus → adoptive cellular immunotherapy → immune checkpoint inhibitor therapy. Conclusion Immunotherapy for liver cancer has undergone continuous development in the recent ten years, and with the research and development of tumor vaccine therapy, oncolytic virus, and immune checkpoint inhibitors and the improvement of immune checkpoint inhibitors, combined treatment based on immunotherapy is expected to further improve the clinical outcome of liver cancer.
- Carcinoma, Hepatocellular /
- Immunotherapy /
- Bibliometrics /
- CiteSpace

HTML全文

表 1 载文量TOP10期刊

排名	期刊名	载文量(篇)	影响因子
1	Journal for Immunotherapy of Cancer	61	10.252
2	Oncoimmunology	51	5.869
3	Oncotarget	51	5.168
4	Cancer Immunology Immunotherapy	49	5.442
5	PLoS One	39	2.74
6	Oncology Letters	33	2.311
7	Clinical Cancer Research	29	10.107
8	Journal of Hepatology	26	20.582
9	Scientific Reports	26	3.998
10	Hepatology	23	14.679

下载: 导出CSV

表 2 被引次数TOP5文献

第一作者	年份(年)	被引次数(次)	文章题目
El-Khoueiry	2017	1386	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Kaufman	2016	609	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial
Parkhurst	2011	540	T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
Zanganeh	2016	529	Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues
Tauriello	2018	513	TGF beta drives immune evasion in genetically reconstituted colon cancer metastasis

下载: 导出CSV

表 3 高频和高中心性关键词

排名	高频关键词	频次	高中心性关键词	中心性
1	immunotherapy	931	breast cancer	0.06
2	hepatocellular carcinoma	704	ovarian cancer	0.06
3	cancer	541	cancer vaccine	0.06
4	expression	383	natural killer cell	0.05
5	therapy	251	antibody	0.05
6	T cell	240	protein	0.05
7	dendritic cell	222	cytotoxic T lymphocyte	0.05
8	survival	193	ablation	0.05
9	cell	180	response	0.04
10	cancer immunotherapy	164	immune response	0.04
11	chemotherapy	155	antitumor immunity	0.04
12	immunity	138	trial	0.04
13	tumor	135	gene therapy	0.04
14	activation	122	gene expression	0.04
15	lymphocyte	117	prostate cancer	0.04
16	melanoma	116	angiogenesis	0.04
17	blockade	110	immunization	0.04
18	nivolumab	109	hepatiti	0.04
19	regulatory T cell	109	gemcitabine	0.04
20	prognosis	107	interferon gamma	0.04

下载: 导出CSV

表 4 关键词聚类分析结果

关键词簇	关键词(按频次从高至低顺序排列)
Cell	cell; inflammation; hepatocellular carcinoma; cancer; progression; microenvironment; apoptosis; tumor microenvironment; expression; NF-κB; liver; growth; macrophages; inhibition; target; tumor; therapy; mechanism; immune; metastasis; STAT3; macrophage; tumor associated macrophage; tumor-associated macrophages; activation; ipilimumab; migration; hypoxia; antitumor; immunity
Vaccine	vaccine; epitope; DNA vaccine; cancer vaccine; marker; cancer vaccines; vaccination; adjuvant; hepatitis B virus; PD-L1; HBV; nivolumab; PD-1; cancer/testis antigen; oncofetal antigen; MAGE-C1; NY-ESO-1; β-catenin; MAGE-A10; pulsed dendritic cell; tumour-associated antigen; cross-presentation; T cell receptor; cytotoxic T cells; adoptive transfer; adoptive cell therapy; poor prognosis; metastasis; protein
Sorafenib	sorafenib; HCC; liver cancer; antitumor immunity; prognosis; targeted therapy; ablation; combination; lenvatinib; drug therapy; oncolytic virus; stage; phase Ⅲ trial; survival time; tumor infiltrating lymphocyte; COVID-19; programmed cell death 1 receptor; radioembolization; trial design; established tumor; hepatic metastase; liver transplantation; staging system; CpG-ODN; interventional oncology; melanoma; cryoablation; regorafenib; nomogram; expression
Cancer immunotherapy	cancer immunotherapy; in vivo; receptor; antitumor activity; cytotoxicity; T cell; CD8⁺ T cell; gamma delta T cells; NK cell; NKG2D; nivolumab; gene therapy; natural killer cells; dendritic cell; nanoparticles; tumor targeting; natural killer cell; chimeric antigen receptor; proliferation; lymphocyte; cytokines; tumor-infiltrating; cytokine; phase Ⅰ trial; costimulatory and inhibitory T-cell receptors; immunological effector cell; nanoparticle; DAP10; mesenchymal stem cell

下载: 导出CSV

表 5 肝癌免疫治疗研究相关突显词出现的年度排序(TOP25)

关键词	年份(年)	强度	起始年(年)	终止年(年)	2011年—2020年
dendritic cell	2011	16.52	2011	2013	▃▃▃▂▂▂▂▂▂▂
adoptive immunotherapy	2011	8.23	2011	2016	▃▃▃▃▃▃▂▂▂▂
in vivo	2011	7.5	2011	2013	▃▃▃▂▂▂▂▂▂▂
cytotoxic T lymphocyte	2011	7.4	2011	2015	▃▃▃▃▃▂▂▂▂▂
vaccine	2011	7.06	2011	2013	▃▃▃▂▂▂▂▂▂▂
gene therapy	2011	6.88	2011	2014	▃▃▃▃▂▂▂▂▂▂
cytokine-induced killer cell	2011	6.79	2011	2016	▃▃▃▃▃▃▂▂▂▂
alpha fetoprotein	2011	6.79	2011	2016	▃▃▃▃▃▃▂▂▂▂
T cell response	2011	6.61	2011	2013	▃▃▃▂▂▂▂▂▂▂
interleukin 2	2011	5.91	2011	2016	▃▃▃▃▃▃▂▂▂▂
immune response	2011	5.32	2011	2012	▃▃▂▂▂▂▂▂▂▂
tumor immunity	2011	4.79	2011	2014	▃▃▃▃▂▂▂▂▂▂
adenovirus	2011	4.62	2011	2015	▃▃▃▃▃▂▂▂▂▂
renal cell carcinoma	2011	4.48	2011	2012	▃▃▂▂▂▂▂▂▂▂
pancreatic cancer	2011	8.51	2012	2014	▂▃▃▃▂▂▂▂▂▂
tumor cell	2011	4.49	2012	2014	▂▃▃▃▂▂▂▂▂▂
phase Ⅱ	2011	4.5	2013	2016	▂▂▃▃▃▃▂▂▂▂
hepatocellularcarcinoma	2011	6.04	2014	2016	▂▂▂▃▃▃▂▂▂▂
CIK cell	2011	5.77	2014	2016	▂▂▂▃▃▃▂▂▂▂
adjuvant	2011	4.61	2016	2017	▂▂▂▂▂▃▃▂▂▂
tumor growth	2011	4.55	2016	2018	▂▂▂▂▂▃▃▃▂▂
solid tumor	2011	5.02	2017	2018	▂▂▂▂▂▂▃▃▂▂
immune checkpoint inhibitor	2011	4.96	2018	2020	▂▂▂▂▂▂▂▃▃▃
PD 1 blockade	2011	4.82	2018	2020	▂▂▂▂▂▂▂▃▃▃
checkpoint inhibitor	2011	4.61	2018	2020	▂▂▂▂▂▂▂▃▃▃

下载: 导出CSV

参考文献(15)

[1]	SUN KX, ZHENG RS, ZHANG SW, et al. Report of cancer incidence and mortality in different areas of China, 2015[J]. China Cancer, 2019, 28(1): 1-11. DOI: 10.11735/j.issn.1004-0242.2019.01.A001. 孙可欣, 郑荣寿, 张思维, 等. 2015年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2019, 28(1): 1-11. DOI: 10.11735/j.issn.1004-0242.2019.01.A001.
[2]	YUAN SX, ZHOU WP. Progress and hot spots of comprehensive treatment for primary liver cancer[J]. Chin J Dig Surg, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776. 袁声贤, 周伟平. 原发性肝癌综合治疗的进展和热点[J]. 中华消化外科杂志, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776.
[3]	HOLLEBECQUE A, MALKA D, FERTÉ C, et al. Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons[J]. Eur J Cancer, 2015, 51(3): 327-339. DOI: 10.1016/j.ejca.2014.12.005.
[4]	LIANG J, LI L. Progress and consideration of immunotherapy strategy for hepatocellular carcinoma[J]. Chin J Dig Surg, 2021, 20(2): 184-190. DOI: 10.3760/cma.j.cn115610-20201228-00809. 梁军, 李丽. 肝癌免疫治疗策略的进展与思考[J]. 中华消化外科杂志, 2021, 20(2): 184-190. DOI: 10.3760/cma.j.cn115610-20201228-00809.
[5]	YAO L, HUI L, YANG Z, et al. Freshwater microplastics pollution: Detecting and visualizing emerging trends based on Citespace Ⅱ[J]. Chemosphere, 2020, 245: 125627. DOI: 10.1016/j.chemosphere.2019.125627.
[6]	MURRAY AG, WARDEH M, MCINTYRE KM. Using the H-index to assess disease priorities for salmon aquaculture[J]. Prev Vet Med, 2016, 126: 199-207. DOI: 10.1016/j.prevetmed.2016.02.007.
[7]	EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
[8]	NAKAMOTO Y, MIZUKOSHI E, KITAHARA M, et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization[J]. Clin Exp Immunol, 2011, 163(2): 165-177. DOI: 10.1111/j.1365-2249.2010.04246.x.
[9]	HUANG H, LIU Y, LIAO W, et al. Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy[J]. Nat Commun, 2019, 10(1): 4801. DOI: 10.1038/s41467-019-12794-2.
[10]	ROSEWELL SHAW A, SUZUKI M. Oncolytic viruses partner with T-cell therapy for solid tumor treatment[J]. Front Immunol, 2018, 9: 2103. DOI: 10.3389/fimmu.2018.02103.
[11]	WANG Y, YANG X, YU Y, et al. Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells[J]. J Cancer, 2018, 9(2): 275-287. DOI: 10.7150/jca.22176.
[12]	KOJIMA Y, VOLKMER JP, MCKENNA K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis[J]. Nature, 2016, 536(7614): 86-90. DOI: 10.1038/nature18935.
[13]	BARKAL AA, WEISKOPF K, KAO KS, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy[J]. Nat Immunol, 2018, 19(1): 76-84. DOI: 10.1038/s41590-017-0004-z.
[14]	SANGRO B, GOMEZ-MARTIN C, de la MATA M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol, 2013, 59(1): 81-88. DOI: 10.1016/j.jhep.2013.02.022.
[15]	LEE MS, RYOO BY, HSU CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma(GO30140): Anopen-label, multicentre, phase 1b study[J]. Lancet Oncol, 2020, 21(6): 808-820. DOI: 10.1056/NEJMoa1915745.